

**Table 2:** Clinical characteristics of the 58 psoriasis patients enrolled in this study investigating the effect of resilience and other clinical variables on depressive symptoms' severity.

Variables	Group A	Group B	Statistical analyses	Effect size
	(BDI-II ≤17) n =39 (67.2 %)	(BDI-II >17) n =19 (32.8 %)		
<b>Duration of psoriasis (years)</b>	14.10 ± 10.99	15.63 ± 12.05	t(56) =0.482, p =0.632	d =0.135
<b>PASI</b>	6.77 ± 9.32	5.81 ± 8.88	Z =0.186, p =0.852	d =0.105
<b>PGA</b>	5 ± 1.7	1.55 ± 1.46	Z =0.28, p =0.779	d =0.097
<b>BSA</b>	63 ± 12.82	5.32 ± 7.5	Z =1.38, p =0.168	d =0.652
<b>Psoriasis symptoms on the face</b>				
Present	13 (33.3 %)	8 (42.1 %)	$\chi^2_{(2)}=0.426$ , p =0.514	$\phi =0.086$
Absent	26 (66.7 %)	11 (57.9 %)		
<b>Psoriasis symptoms on the torso</b>				
Present	13 (33.3 %)	12 (63.2 %)	$\chi^2_{(2)}=0.07$ , p =0.792	$\phi =0.035$
Absent	26 (66.7 %)	7 (36.8 %)		
<b>Psoriatic arthritis</b>				
Present	6 (15.4 %)	1 (5.3 %)	$\chi^2_{(2)}=1.233$ , p =0.267	$\phi =0.146$
Absent	33 (84.6 %)	18 (94.7 %)		
<b>Other physical illness</b>				
Present	14 (35.9 %)	12 (63.2 %)	$\chi^2_{(1)}=3.839$ , p =0.05	$\phi =0.257$
Absent	25 (64.1 %)	7 (36.8 %)		
<b>Past depressive episodes</b>				
Present	11 (28.2 %)	7 (36.8 %)	$\chi^2_{(2)}=0.445$ , p =0.505	$\phi =0.088$
Absent	28 (71.8 %)	12 (63.2 %)		
<b>BDI-II</b>	7.95 ± 4.75	28.42 ± 9.22	t(22.771) =9.101, p <0.001	d =2.546
<b>RS</b>	144.67 ± 13.81	115.53 ± 29.3	Z =3.812, p <0.001	d =1.152

Values are given as means ± standard deviation or as number with percentage in brackets.. BDI-II: Beck Depression Inventory-II, n: number, PASI: Psoriasis Area and Severity Index, PGI: Physician Global Assessment, BSA: Body Surface Area, RS: Resilience Scale.